

July 8, 2026

SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

Completion of Early Redemption of the 1st Unsecured Straight Bonds

TOKYO, Japan, July 8, 2026—SymBio Pharmaceuticals Limited (TSE: 4582) (“SymBio” or the “Company”) hereby announces the completion of early redemptions of the 1st unsecured straight bonds issued on August 26, 2025 to EVO FUND (the “Bonds”). Details are as set forth below.

I. Early redemption status of the Bonds as of July 7th

1.	Name of bonds	SymBio Pharmaceuticals Limited 1st Unsecured Straight Bonds
2.	Allottee	EVO FUND
3.	Payment date	August 26, 2025
4.	Issue price	¥1,235,000,000
5.	Outstanding balance of bonds as of the date of the previous disclosure*1	¥227,500,000
6.	Total amount of bonds redeemed prior to maturity since the previous disclosure	¥227,500,000*2
7.	Outstanding balance of bonds as of July 7th	¥0

*1. Please refer to the “Notice Regarding Conversion of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights Issued through Third-Party Allotment, Early Redemption of the 1st Unsecured Straight Bonds, and Change in the Scheduled Timing of Expenditures of Funds Raised through the 65th to 67th Stock Acquisition Rights”, released on March 23, 2026.

*2. The early redemption of the Bonds was funded in part by proceeds paid in upon the exercise of the 66th stock acquisition rights.

For details on the Bonds, please see the “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights,” released on July 22, 2025, and the “Notice Regarding the Completion of Payment for the 1st Unsecured Straight Bonds,” released on August 26, 2025.